Menopause is associated with increased prevalence of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Journal
Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
pubmed:
3
2
2023
medline:
25
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
Data are inconsistent on whether menopause is a risk for nonalcoholic fatty liver disease (NAFLD). Using systematic review and meta-analysis, we aimed to collect all available data to determine the association between menopause and NAFLD. Potentially eligible studies were identified from EMBASE, MEDLINE, and Web of Science databases from inception to December 2021 using a search strategy that was composed of the terms for "NAFLD" and "menopause." Eligible study must contain two groups of participants: one group of postmenopausal women and another group of premenopausal women. Then, the study must report the association between menopause and prevalent NAFLD. We extracted such data from each study and calculated pooled odds ratio (OR) by combining effect estimates of each study using a random-effects model. Funnel plot was used to assess for the presence of publication bias. A total of 587 articles were identified. After two rounds of independent review by two investigators, 12 cross-sectional studies fulfilled the eligibility criteria. The meta-analysis of 12 studies revealed the significant association between menopause and NAFLD with a pooled OR of 2.37 (95% CI, 1.99-2.82; I2 = 73%). The association remained significant in a sensitivity meta-analysis of six studies that reported the association with adjustment for age and metabolic factors with a pooled OR of 2.19 (95% CI, 1.73-2.78; I2 = 74%). The funnel plot was fairly symmetric and was not suggestive of publication bias. The meta-analysis reveals that menopausal status was associated with approximately 2.4 times higher odds of NAFLD.
Identifiants
pubmed: 36728528
doi: 10.1097/GME.0000000000002133
pii: 00042192-202303000-00018
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
348-354Informations de copyright
Copyright © 2023 by The North American Menopause Society.
Déclaration de conflit d'intérêts
Financial disclosure/conflicts of interest: None reported.
Références
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84. doi: 10.1002/hep.28431
doi: 10.1002/hep.28431
Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64:1577–1586. doi: 10.1002/hep.28785
doi: 10.1002/hep.28785
Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep 2016;6:33386. doi: 10.1038/srep33386
doi: 10.1038/srep33386
Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 2018;41:372–382. doi: 10.2337/dc17-1902
doi: 10.2337/dc17-1902
Shen H, Lipka S, Kumar A, Mustacchia P. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis. J Gastrointest Oncol 2014;5:440–446. doi: 10.3978/j.issn.2078-6891.2014.061
doi: 10.3978/j.issn.2078-6891.2014.061
DiStefano JK. NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment. Endocrinology 2020;161:bqaa134. doi: 10.1210/endocr/bqaa134
doi: 10.1210/endocr/bqaa134
Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021;110:921–937. doi: 10.1007/s00392-020-01709-7
doi: 10.1007/s00392-020-01709-7
Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 2019;70:1457–1469. doi: 10.1002/hep.30626
doi: 10.1002/hep.30626
Castellana M, Donghia R, Guerra V, et al. Performance of fatty liver index in identifying non-alcoholic fatty liver disease in population studies. A meta-analysis. J Clin Med 2021;10:1877. doi: 10.3390/jcm10091877
doi: 10.3390/jcm10091877
Wells GSB, O'Connell D, Peterson J, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Available at: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed July 10, 2022.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188. doi: 10.1016/0197-2456(86)90046-2. Accessed July 10, 2022
doi: 10.1016/0197-2456(86)90046-2
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560. doi: 10.1136/bmj.327.7414.557
doi: 10.1136/bmj.327.7414.557
Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21(1, pt 1):138–143. doi: 10.1111/j.1440-1746.2005.04086.x
doi: 10.1111/j.1440-1746.2005.04086.x
Völzke H, Schwarz S, Baumeister SE, et al. Menopausal status and hepatic steatosis in a general female population. Gut 2007;56:594–595. doi: 10.1136/gut.2006.115345
doi: 10.1136/gut.2006.115345
Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010;9:402–409.
Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol 2012;18:237–243. doi: 10.3748/wjg.v18.i3.237
doi: 10.3748/wjg.v18.i3.237
Sanghavi M, Turer A, Neeland I, Ayers C, Lemos JD, Khera A. Postmenopausal status is independently associated with advanced hepatic steatosis: the Dallas Heart Study. J Am Coll Cardiol 2013;61(10_Supplement):E1429. doi: 10.1016/S0735-1097(13)61429-1
doi: 10.1016/S0735-1097(13)61429-1
Chung GE, Yim JY, Kim D, et al. The influence of metabolic factors for nonalcoholic fatty liver disease in women. Biomed Res Int 2015;2015:131528. doi: 10.1155/2015/131528
doi: 10.1155/2015/131528
Ryu S, Suh BS, Chang Y, et al. Menopausal stages and non-alcoholic fatty liver disease in middle-aged women. Eur J Obstet Gynecol Reprod Biol 2015;190:65–70. doi: 10.1016/j.ejogrb.2015.04.017
doi: 10.1016/j.ejogrb.2015.04.017
Morrill K, Lee M, Garcia D, et al. Associations between menopausal status and lifestyle behaviors among Mexican-origin women with non-alcoholic fatty liver disease. Hepatology 2019;70(S1):188–1382. doi: 10.1002/hep.30941
doi: 10.1002/hep.30941
Chen Y, Huang Q, Ai P, et al. Association between serum uric acid and non-alcoholic fatty liver disease according to different menstrual status groups. Can J Gastroenterol Hepatol 2019;2019:2763093. doi: 10.1155/2019/2763093
doi: 10.1155/2019/2763093
Setroame AM, Kormla Affrim P, Abaka-Yawson A, et al. Prevalence of metabolic syndrome and nonalcoholic fatty liver disease among premenopausal and postmenopausal women in Ho Municipality: a cross-sectional study. Biomed Res Int 2020;2020:2168381. doi: 10.1155/2020/2168381
doi: 10.1155/2020/2168381
Bao T, Ying Z, Gong L, et al. Association between serum uric acid and nonalcoholic fatty liver disease in nonobese postmenopausal women: a cross-sectional study. Sci Rep 2020;10:10072. doi: 10.1038/s41598-020-66931-9
doi: 10.1038/s41598-020-66931-9
Meraglia F, Pezzuoli C, Anesi S, et al. Menopause as determinant of fatty liver index at population level. Clinical Nutrition ESPEN 2021;46:S621. doi: 10.1016/j.clnesp.2021.09.225
doi: 10.1016/j.clnesp.2021.09.225
Burger HG, Dudley EC, Robertson DM, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Horm Res 2002;57:257–275. doi: 10.1210/rp.57.1.257
doi: 10.1210/rp.57.1.257
Florio AA, Graubard BI, Yang B, et al. Oophorectomy and risk of non-alcoholic fatty liver disease and primary liver cancer in the Clinical Practice Research Datalink. Eur J Epidemiol 2019;34:871–878. doi: 10.1007/s10654-019-00526-1
doi: 10.1007/s10654-019-00526-1
Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649–1657. doi: 10.1053/gast.2002.33573
doi: 10.1053/gast.2002.33573
Klair JS, Yang JD, Abdelmalek MF, et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 2016;64:85–91. doi: 10.1002/hep.28514
doi: 10.1002/hep.28514
Ko SH, Kim HS. Menopause-associated lipid metabolic disorders and foods beneficial for postmenopausal women. Nutrients 2020;12:202. doi: 10.3390/nu12010202
doi: 10.3390/nu12010202
Chen KL, Madak-Erdogan Z. Estrogens and female liver health. Steroids 2018;133:38–43. doi: 10.1016/j.steroids.2017.10.015
doi: 10.1016/j.steroids.2017.10.015
Abildgaard J, Ploug T, Al-Saoudi E, et al. Changes in abdominal subcutaneous adipose tissue phenotype following menopause is associated with increased visceral fat mass. Sci Rep 2021;11:14750. doi: 10.1038/s41598-021-94189-2
doi: 10.1038/s41598-021-94189-2
Sun Y, Liu B, Snetselaar LG, et al. Association of normal-weight central obesity with all-cause and cause-specific mortality among postmenopausal women. JAMA Netw Open 2019;2:e197337. doi: 10.1001/jamanetworkopen.2019.7337
doi: 10.1001/jamanetworkopen.2019.7337
Lee HW, Kim KJ, Jung KS, et al. The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PLoS One 2017;12:e0187066. doi: 10.1371/journal.pone.0187066
doi: 10.1371/journal.pone.0187066
Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. Adv Exp Med Biol 2017;1043:227–256. doi: 10.1007/978-3-319-70178-3_12
doi: 10.1007/978-3-319-70178-3_12
Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 2013;34:309–338. doi: 10.1210/er.2012-1055
doi: 10.1210/er.2012-1055
Yang M, Ma F, Guan M. Role of steroid hormones in the pathogenesis of nonalcoholic fatty liver disease. Metabolites 2021;11:320. doi: 10.3390/metabo11050320
doi: 10.3390/metabo11050320
Qiu S, Vazquez JT, Boulger E, et al. Hepatic estrogen receptor α is critical for regulation of gluconeogenesis and lipid metabolism in males. Sci Rep 2017;7:1661. doi: 10.1038/s41598-017-01937-4
doi: 10.1038/s41598-017-01937-4
Koo SH. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 2013;19:210–215. doi: 10.3350/cmh.2013.19.3.210
doi: 10.3350/cmh.2013.19.3.210
Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010;103:71–83. doi: 10.1093/qjmed/hcp158
doi: 10.1093/qjmed/hcp158
Borrás C, Gambini J, López-Grueso R, Pallardó FV, Viña J. Direct antioxidant and protective effect of estradiol on isolated mitochondria. Biochim Biophys Acta 2010;1802:205–211. doi: 10.1016/j.bbadis.2009.09.007
doi: 10.1016/j.bbadis.2009.09.007
Gameiro CM, Romão F, Castelo-Branco C. Menopause and aging: changes in the immune system—a review. Maturitas 2010;67:316–320. doi: 10.1016/j.maturitas.2010.08.003
doi: 10.1016/j.maturitas.2010.08.003
Campbell SE, Febbraio MA. Effect of ovarian hormones on mitochondrial enzyme activity in the fat oxidation pathway of skeletal muscle. Am J Physiol Endocrinol Metab 2001;281:E803–E808. doi: 10.1152/ajpendo.2001.281.4.E803
doi: 10.1152/ajpendo.2001.281.4.E803
Serviente C, Tuomainen TP, Virtanen J, Witkowski S, Niskanen L, Bertone-Johnson E. Follicle-stimulating hormone is associated with lipids in postmenopausal women. Menopause 2019;26:540–545. doi: 10.1097/gme.0000000000001273
doi: 10.1097/gme.0000000000001273
Fröhlich E, Wahl R. Insight into potential interactions of thyroid hormones, sex hormones and their stimulating hormones in the development of non-alcoholic fatty liver disease. Metabolites 2022;12:718. doi: 10.3390/metabo12080718
doi: 10.3390/metabo12080718